- Report
- September 2026
- 187 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- September 2026
- 181 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- September 2026
- 195 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- September 2026
- 189 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- September 2026
- 193 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- February 2026
- 250 Pages
Global
From €4166EUR$4,490USD£3,475GBP
- Report
- February 2026
- 250 Pages
Global
From €4166EUR$4,490USD£3,475GBP
- Report
- September 2026
- 180 Pages
Global
From €3289EUR$3,545USD£2,744GBP
€3655EUR$3,939USD£3,049GBP
- Report
- August 2026
- 337 Pages
Global
From €2320EUR$2,500USD£1,935GBP
- Report
- August 2026
- 160 Pages
Global
From €3081EUR$3,320USD£2,570GBP
€3851EUR$4,150USD£3,212GBP
- Report
- August 2023
- 250 Pages
Global
From €2310EUR$2,490USD£1,927GBP
- Report
- August 2025
- 150 Pages
Global
From €5521EUR$5,950USD£4,605GBP
- Report
- May 2025
- 100 Pages
Global
From €5521EUR$5,950USD£4,605GBP
- Report
- May 2025
- 100 Pages
Global
From €5521EUR$5,950USD£4,605GBP
- Report
- October 2024
- 100 Pages
Global
From €5521EUR$5,950USD£4,605GBP
From €4547EUR$4,900USD£3,793GBP
- Report
- May 2024
- 200 Pages
Global
From €3851EUR$4,150USD£3,212GBP
- Report
- November 2024
- 110 Pages
United States
From €5521EUR$5,950USD£4,605GBP
- Report
- June 2023
- 118 Pages
Global
From €4176EUR$4,500USD£3,483GBP
- Report
- December 2022
- 118 Pages
Global
From €4176EUR$4,500USD£3,483GBP

The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more